Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Clinical Trial Title

Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping

National Clinical Trial Number:

NCT03927027

Clinical Trial Protocol Description:

This phase III trial studies how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent lymphedema after surgery.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have no prior axillary surgery except needle biopsy or concurrent SLNB.
  • Have no history of lymphedema of either arm.
  • Aree female and 18 years of age or older.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Cristina O'Donoghue

Contact Information

Rush Cancer Center Clinical Trials Office